| Literature DB >> 34981283 |
Giuseppe Micieli1, Anna Cavallini2, Pietro Cortelli3,4, Federico Rea5,6.
Abstract
OBJECTIVE: This study aims to assess whether the role of neurologists in the emergency department changed during the coronavirus (COVID)-19 pandemic.Entities:
Keywords: COVID-19; Emergency room; Neurologist; Survey
Mesh:
Year: 2022 PMID: 34981283 PMCID: PMC8723809 DOI: 10.1007/s10072-021-05779-x
Source DB: PubMed Journal: Neurol Sci ISSN: 1590-1874 Impact factor: 3.830
Percentage distributions of triage level according to SARS-CoV-2 infection
| Triage level | Patients with the SARS-CoV-2 infection | Other patients |
|---|---|---|
| White/ambulatory complaints | 3% | 8% |
| Green/slightly urgent | 28% | 34% |
| Yellow/urgent | 31% | 41% |
| Red/emergency | 38% | 17% |
Fig. 1Percentage distributions of triage level assigned by emergency physicians and neurologists
Fig. 2Percentage distributions of request appropriateness among triage levels assigned by emergency physicians
Distribution of the reasons for neurological consultation
| Reasons for the consultation | 2019 | 2020 | SMD |
|---|---|---|---|
| Focal neurological deficits | 21.2% | 22.8% | 0.038 |
| Transient loss of consciousness | 12.8% | 11.5% | 0.041 |
| Headache | 12.5% | 6.5% | 0.205 |
| Strength deficiency or sensory disturbances | 11.5% | 9.3% | 0.072 |
| Dizziness | 9.1% | 7.7% | 0.052 |
| Epileptic manifestation | 8.6% | 10.9% | 0.078 |
| Delirium/acute confusional state | 7.3% | 7.6% | 0.011 |
| Head trauma | 5.2% | 5.2% | 0.001 |
| Acute visual disturbances | 4.4% | 3.9% | 0.024 |
| Muscle pain | 1.9% | 0.5% | 0.122 |
| Coma | 1.5% | 3.7% | 0.141 |
| Fever and neurological signs | 1.5% | 0.4% | 0.108 |
| Paraplegia/quadriplegia | 1.1% | 1.1% | 0.001 |
| Movement disorders (hyper- or hypokinesia) | 1.0% | 1.2% | 0.018 |
| Functional/psychiatric disorders | 0.7% | 1.7% | 0.093 |
| Other reason | 0.0% | 6.1% | - |
SMD, standardized mean difference
Distribution of diagnostic hypotheses formulated by the neurologists after consultations
| Diagnoses | 2019 | 2020 | SMD |
|---|---|---|---|
| Ischemic stroke | 16.2% | 18.0% | 0.048 |
| Transient ischemic attack | 9.4% | 8.4% | 0.035 |
| Primary headache | 8.3% | 4.3% | 0.163 |
| Seizure in known epilepsy | 5.7% | 7.6% | 0.074 |
| Cardiogenic syncope | 5.6% | 3.7% | 0.093 |
| Peripheral vertigo | 5.6% | 5.8% | 0.007 |
| First epileptic seizure | 5.3% | 7.6% | 0.096 |
| Head trauma | 4.8% | 4.1% | 0.032 |
| Monoradiculo-plexopathy | 4.2% | 4.3% | 0.007 |
| Symptomatic headache | 3.6% | 3.4% | 0.012 |
| Psychiatric disorder | 3.6% | 3.4% | 0.012 |
| Delirium in dementia | 3.2% | 3.7% | 0.026 |
| Central vertigo | 3.1% | 2.0% | 0.070 |
| Neurologic syncope | 3.0% | 3.1% | 0.003 |
| Metabolic encephalopathy | 2.0% | 3.1% | 0.064 |
| Discopathy | 1.9% | 0.3% | 0.154 |
| Cerebral hemorrhage | 1.7% | 2.6% | 0.068 |
| CNS cancer | 1.7% | 2.3% | 0.048 |
| CNS infection (encephalitis, meningitis, meningoencephalitis, encephalomyelitis) | 1.6% | 0.7% | 0.077 |
| Multiple sclerosis | 1.5% | 1.5% | 0.001 |
| Aggravation of Parkinson’s disease | 1.2% | 0.7% | 0.044 |
| Subdural hematoma | 0.8% | 1.6% | 0.074 |
| Subarachnoid hemorrhage | 0.7% | 1.1% | 0.040 |
| Status epilepticus | 0.2% | 1.5% | 0.141 |
| Othera | 5.1% | 5.2% | 0.004 |
aNeurological conditions with a frequency lower than 1% in 2019 and 2020
CNS, central nervous system; SMD, standardized mean difference
Tests and other consultations
available at the time of diagnostic hypothesis
| Tests and consultations | 2019 | 2020 | SMD |
|---|---|---|---|
| Blood chemistry tests | 80.7% | 86.4% | 0.155 |
| Neuroimaging | 75.0% | 82.6% | 0.188 |
| Electrocardiogram | 67.3% | 78.1% | 0.244 |
| Blood gas tests | 24.0% | 34.5% | 0.232 |
| Neurophysiological examinations | 9.8% | 12.9% | 0.096 |
| Cerebral spinal fluid analysis | 1.4% | 1.3% | 0.008 |
SMD, standardized mean difference